Simcere Pharma’s $1.53B Roche Deal Catapults Stock to New Heights
Simcere Pharma’s $1.53 B licensing deal with Roche propels its B‑cell tri‑specific antibody SIM0660 into global spotlight, catapulting stock and growth prospects.
- SIMCERE PHARMACEUTICAL GROUP
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read